From the Globe and Mail:
Adding a new drug to the standard chemotherapy cocktail can significantly boost the survival rate of patients with the most common type of non-Hodgkin's lymphoma -- the fastest-rising cancer among Canadians, a study has shown.
The study by the B.C. Cancer Agency shows that the addition of the drug rituximab increased two-year survival by more than 50 per cent, compared with using only the standard mix of four chemo drugs. ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment